Petrovax Pharm presents new biotech medicines at BIOPROM-26
Biopharmaceutical company Petrovax Pharm presented its updated portfolio of original medicines at the BIOPROM-26 forum. Denis Manturov, First Deputy Prime Minister of the Russian Federation, visited the company’s stand, where he was introduced to breakthrough Russian innovations: Mentetra®, a new quadrivalent vaccine for the prevention of meningococcal infection, and Areima® (camrelizumab), an innovative oncology medicine. At the forum, Mikhail Tsyferov, President of Petrovax Pharm, also announced the approval of Elefuza® (INN: fuzuloparib), a new targeted medicine that will expand treatment options for patients with aggressive cancers.
Denis Manturov praised Mentetra®, Russia’s first quadrivalent conjugate vaccine for the prevention of meningococcal infection, which received marketing authorization in late September.
Meningitis is one of the most dangerous infections, with a case fatality rate of up to 20%. The availability of a domestically produced vaccine that protects against the four most common meningococcal serogroups (A, C, W, and Y) causing meningitis has significantly expanded opportunities for population immunization. Mentetra® can be administered to children from three months of age and adults up to 55 years of age.
Petrovax Pharm manufactures the meningococcal vaccine through a full production cycle, including synthesis of the active substance. By early next year, production capacity will exceed 6 million doses annually, enabling the company to fully meet the Russian healthcare system’s needs for vaccination against meningococcal infection. Experts note that domestic production creates the necessary conditions for including meningococcal vaccination in the National Immunization Schedule.
At the company’s stand, Denis Manturov was also introduced to Areima® (camrelizumab), an innovative immuno-oncology medicine also manufactured through a full production cycle. It belongs to a new generation of PD-1 inhibitors and helps significantly improve the prognosis for patients with a wide range of cancers. Its list of indications continues to expand: approved in 2024 for the treatment of esophageal and nasopharyngeal cancers, it is now also approved for non-small cell lung cancer and triple-negative breast cancer, a highly aggressive subtype often diagnosed in women under 45.
During BIOPROM, Mikhail Tsyferov, President of Petrovax Pharm, also announced the approval of Elefuza® (INN: fuzuloparib), an original innovative targeted medicine for the treatment of advanced epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and metastatic HER2-negative breast cancer in women with BRCA1/2 mutations. Fuzuloparib is a selective inhibitor of PARP1 and PARP2 proteins. The availability of a new selective PARP inhibitor expands treatment options for aggressive cancers and gives physicians an additional tool for long-term disease control.
Breast cancer is currently the most common malignancy among Russian women, with approximately 80% of cases classified as HER2-negative. Ovarian cancer ranks among the ten most common cancers in women and has a high case fatality rate.
“The approval of innovative targeted cancer medicines in Russia can significantly extend and improve the lives of people in their most active years. This is why Petrovax Pharm is committed to expanding its oncology portfolio. Today, we focus on treatment options that can improve prognosis and quality of life in aggressive cancers most frequently diagnosed in women. Bringing fuzuloparib to the Russian market will significantly improve access to therapy. In doing so, we continue to contribute to protecting and improving the reproductive health of Russian women,”
As Mikhail Tsyferov emphasized, BIOPROM-26 gave Petrovax Pharm an opportunity to present solutions that expand the options for modern treatment and prevention and support the development of Russia’s biopharmaceutical industry.
An original medicine for the targeted treatment of ovarian and HER2-negative breast cancer is authorized in Russia
